Clinical trials: Acute Coronary Syndromes (ACS)
Atrial Fibrillation, Antithrombotic Therapy
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
More than 25% of patients referred for diagnostic coronary angiography and percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS) suffer from non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Antithrombotic Therapy, Acute Coronary Syndrome, Percutaneous Coronary Interventions
- Trial name
- ADONIS-PCI (NCT04695106)
- Testing
- Ticagrelor, Dabigatran Etexilate, Aspirin
- Where
- Poland
- Volunteers
- 1,194 people
- Sponsor
- Medical University of Gdansk
Acute Coronary Syndrome
Potential Drug Interactions With Bisoprolol in Egyptian Patients With ACS
Acute coronary syndrome (ACS) is any group of clinical symptoms compatible with acute myocardial ischemia and includes unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation…
- Trial name
- NCT05536284
- Testing
- Bisoprolol Fumarate Tablets
- Where
- Egypt
- Volunteers
- 128 people
- Sponsor
- Damanhour University
Myocardial Infarction (MI), Acute Coronary Syndrome (ACS)
Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction
The goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based ECG interpretation tool improves the early diagnosis and treatment of occlusion myocardial infarction (OMI) in adults presenting with…
- Trial name
- TITAN-OMI (NCT07077057)
- Testing
- AI-assisted ECG interpretation (PMcardio)
- Where
- Switzerland
- Volunteers
- 500 people
- Sponsor
- Cardiocentro Ticino
Acute Coronary Syndromes (ACS), Cardiac Rehabilitation
Patient-centered Personalized Cardiac Rehabilitation in Post Acute Coronary Syndrome (BREAK-trial)
The primary objective of this study is to compare an integrated, multidisciplinar patient-centered CRP (Cardiac Rehabilitation Program) (intervention group) especially focused on covering the needs for the female and fragile…
- Conditions
- Acute Coronary Syndromes (ACS), Cardiac Rehabilitation, Frailty, Women
- Trial name
- BREAK (NCT07038265)
- Testing
- Personalised treatment, Usual Care
- Where
- Spain
- Volunteers
- 202 people
- Sponsor
- Institut d'Investigació Biomèdica de Bellvitge
Cardiogenic Shock, Acute Coronary Syndrome
Score TO Predict SHOCK - STOP SHOCK
The goal of this international multicenter study is to develop a scoring system to identify the risk of developing cardiogenic shock (CS) in patients suffering from acute coronary syndrome (ACS) utilising artificial intelligence.
- Conditions
- Cardiogenic Shock, Acute Coronary Syndrome, Acute Myocardial Infarction
- Trial name
- NCT05570864
- Where
- Slovakia
- Volunteers
- 50,000 people
- Sponsor
- Premedix Academy
Acute Coronary Syndromes
Targeted Feedback Reports to Improve Acute Coronary Syndromes (ACS) Care
This project is designed to examine the impact of tailored feedback on site performance. The investigators' objective is to evaluate whether a 'personalized and targeted' feedback, education and performance improvement…
- Trial name
- NCT00952250
- Testing
- Targeted Feedback Reports, Targeted Feedback Report
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Duke University
Non ST Segment Elevation Acute Coronary Syndrome, Chronic Kidney Disease
COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS
Ticagrelor, a new P2Y12 receptor antagonist, achieve faster, consistent and higher platelet inhibition than clopidogrel, which was considered more noticeable in patients with ACS combining chronic kidney disease(CKD).
- Trial name
- OPT-CKD (NCT02578537)
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenyang Northern Hospital
Acute Coronary Syndrome
Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), Hepatocyte Growth Factor (HGF) in Patients With Acute Coronary Syndrome (ACS)
The main aim of the study is a comparison of serum and plasma concentration of VEGF (Vascular Endothelial Growth Factor), HGF (Hepatocyte Growth Factor) and PDGF (Platelet Derived Growth Factor) with markers of myocardial injury…
- Trial name
- NCT00844987
- Where
- Poland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Effectiveness of Artificial Intelligent Based mHealth System to Reduce ACS Patients Bleeding Events After PCI
The present study was designed to observe the effectiveness of artificial intelligent based mHealth system(Chronic disease management system) to reduce bleeding events in ACS patients undergoing PCI.
- Conditions
- Acute Coronary Syndrome, Percutaneous Coronary Intervention, Bleeding
- Trial name
- NCT03738930
- Testing
- AI based mHealth system
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Chinese PLA General Hospital
Dyslipidemias
Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS
The study is prospective, open-label, randomized, single-center study involving patients admitted on an emergency basis with an acute coronary syndrome (ACS) clinic who underwent PCI of an infarct-related artery (IRA) and had…
- Trial name
- Combi-LLT ACS (NCT05624658)
- Testing
- Combined Lipid-lowering Therapy
- Where
- Russia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Samara Regional Cardiology Dispensary
Acute Coronary Syndromes (ACS), Chronic Coronary Syndrome
Starring Optical Coherence Tomography During Percutaneous Coronary Intervention Guidance
The starring optical coherence tomography during percutaneous coronary intervention guidance (OCT-AGEM) registry aims to evaluate the clinical impact of intra-procedural optical coherence tomography (OCT) in coronary…
- Conditions
- Acute Coronary Syndromes (ACS), Chronic Coronary Syndrome, MINOCA, INOCA (Ischemia With Non Obstructive Coronary Artery Disease)
- Trial name
- OCT-AGEM (NCT07182799)
- Testing
- Plaque vulnerability assessment, Stent implantation optimization
- Where
- Italy
- Volunteers
- 3,200 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Coronary Artery Disease, Acute Coronary Syndrome
Recurrent Events After Percutaneous Coronary INterventio for ACS
Patients undergoing PCI for ACS are exposed to a significant ischemic and bleeding risk. The aim of our study is instead to analyze in detail the rates of recurrent events, but also their predictors and impact on outcomes, in a…
- Trial name
- AGAIN (NCT03675347)
- Testing
- angioplasty
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Heart Failure, Acute Coronary Syndrome
Timing of Coronary Angiography in NSTE-ACS With ADHF
The investigators hypothesized that immediate coronary angiography (CAG) within 2 hours after admission can reduce mortality compared to delayed CAG after stabilization of acute decompensated heart failure (ADHF) in patients with…
- Trial name
- EARLY-HF (NCT04810806)
- Testing
- Immediate coronary angiography within 2 hours after randomization, Delayed coronary angiography after stabilization of heart failure
- Where
- South Korea
- Volunteers
- 316 people
- Sponsor
- Chonnam National University Hospital
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), Hypercholerolemia
Cardiovascular-kidney-metabolic (CKM)-Guided Therapy for Patients After Acute Coronary Syndrome
Patients with a history of myocardial infarction are at significantly increased risk of recurrent cardiovascular events. Despite established clinical guidelines, secondary preventive care is often initiated too late, inadequate…
- Conditions
- Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), Hypercholerolemia, Hypertension, Diabete Mellitus
- Trial name
- SLIM-3 (NCT07773272)
- Testing
- Rapid ESC-guideline based secondary prevention following myocardial infaction
- Where
- Netherlands
- Volunteers
- 1,215 people
- Sponsor
- Zuyderland Medisch Centrum
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR
The aim of this study is to assess the safety and efficacy of the CYP2C19 genotype-guided abbreviated dual antiplatelet therapy (DAPT) strategy versus the un-guided stepwise intensity de-escalation of DAPT strategy in patients…
- Trial name
- GUIDE-HBR (NCT06763744)
- Testing
- P2Y12 antagonist monotherapy, clopidogrel + aspirin
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Samsung Medical Center
Acute Coronary Syndrome
Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndrome (ACS)
Release of troponin evaluated by the peak of troponin during the hospital phase.Because of its sensitivity and specificity as well as its widespread use in routine practice, rise in troponin levels is the main assessment criteria…
- Trial name
- ABOARD (NCT00442949)
- Testing
- Catheterization immediate PCI, delayed PCI
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cardiac Rehabilitation, Acute Coronary Syndrome
The Influence of Cardiac Rehabilitation on the Health State After ACS
Coronary heart disease, including acute coronary syndromes (ACS), is the leading cause of death in European countries. One of the basic elements of secondary and tertiary prevention of ACS is cardiac rehabilitation.
- Trial name
- CARDIO-REH (NCT03935438)
- Testing
- Cardiac rehabilitation
- Where
- Poland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Poznan University of Medical Sciences
Non ST Segment Elevation Acute Coronary Syndrome
Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI
It is designed to test the hypothesis that high loading dose(360mg) ticagrelor versus conventional loading dose(180mg) will result in a higher inhibition of platelet aggregation(IPA) without increasing the bleeding events.
- Trial name
- NCT01962428
- Testing
- ticagrelor
- Where
- 2 sites in China
- Volunteers
- 250 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR)
Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy
Study Purpose Coronary heart disease (CAD) is a leading global cause of death, with Acute Coronary Syndrome (ACS) as its acute and life-threatening subtype.
- Conditions
- Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR), Coronary Artery Disease (CAD)
- Trial name
- NCT07354828
- Where
- China
- Volunteers
- 3,500 people
- Sponsor
- Shenyang Northern Hospital
Acute Coronary Syndromes
Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry
The primary objective of the UPSTREAM Registry is to address the data gap regarding the course of NSTEMI (Non-ST-Elevation Myocardial Infarction)between ED (Emergency Department) arrival and diagnostic angiography in detail, by…
- Trial name
- NCT02271022
- Testing
- Non-Interventional Study
- Where
- 55 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca